Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Given as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and in HIV-Exposed Uninfected Infants in Republic of South Africa
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics; Registrational
- Sponsors sanofi pasteur
- 29 Jan 2018 Planned End Date changed from 28 Mar 2018 to 1 Feb 2019.
- 24 Nov 2017 Planned End Date changed from 11 Sep 2018 to 28 Mar 2018.
- 24 Nov 2017 Planned primary completion date changed from 11 Sep 2018 to 28 Mar 2018.